These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 20954968)

  • 1. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
    Findlow J; Borrow R; Snape MD; Dawson T; Holland A; John TM; Evans A; Telford KL; Ypma E; Toneatto D; Oster P; Miller E; Pollard AJ
    Clin Infect Dis; 2010 Nov; 51(10):1127-37. PubMed ID: 20954968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Mutant FHbp Elicits Higher Protective Antibody Responses in Infant Rhesus Macaques than a Licensed Serogroup B Vaccine.
    Beernink PT; Vianzon V; Lewis LA; Moe GR; Granoff DM
    mBio; 2019 Jun; 10(3):. PubMed ID: 31213564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic characterization and estimated 4CMenB vaccine strain coverage of 284
    Efron A; Brozzi A; Biolchi A; Bodini M; Giuliani M; Guidotti S; Lorenzo F; Moscoloni MA; Muzzi A; Nocita F; Pizza M; Rappuoli R; Tomei S; Vidal G; Vizzotti C; Campos J; Sorhouet Pereira C
    Hum Vaccin Immunother; 2024 Dec; 20(1):2378537. PubMed ID: 39037011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study.
    Chiu NC; Huang LM; Willemsen A; Bhusal C; Arora AK; Reynoso Mojares Z; Toneatto D
    Hum Vaccin Immunother; 2018 May; 14(5):1075-1083. PubMed ID: 29337653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-component meningococcal serogroup B (MenB)-4C vaccine induces effective opsonophagocytic killing in children with a complement deficiency.
    van den Broek B; van Els CACM; Kuipers B; van Aerde K; Henriet SS; de Groot R; de Jonge MI; Langereis JD; van der Flier M
    Clin Exp Immunol; 2019 Dec; 198(3):381-389. PubMed ID: 31487400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broad vaccine protection against Neisseria meningitidis using factor H binding protein.
    Findlow J; Bayliss CD; Beernink PT; Borrow R; Liberator P; Balmer P
    Vaccine; 2020 Nov; 38(49):7716-7727. PubMed ID: 32878710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate.
    Hung MC; Salim O; Williams JN; Heckels JE; Christodoulides M
    Infect Immun; 2011 Sep; 79(9):3784-91. PubMed ID: 21708989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of invasive Neisseria meningitidis strains from Québec, Canada, during a period of increased serogroup B disease, 2009-2013: phenotyping and genotyping with special emphasis on the non-carbohydrate protein vaccine targets.
    Law DK; Lefebvre B; Gilca R; Deng S; Zhou J; De Wals P; Tsang RS
    BMC Microbiol; 2015 Jul; 15():143. PubMed ID: 26204985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents.
    Boutriau D; Poolman J; Borrow R; Findlow J; Domingo JD; Puig-Barbera J; Baldó JM; Planelles V; Jubert A; Colomer J; Gil A; Levie K; Kervyn AD; Weynants V; Dominguez F; Barberá R; Sotolongo F
    Clin Vaccine Immunol; 2007 Jan; 14(1):65-73. PubMed ID: 17065257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.
    Wedege E; Bolstad K; Aase A; Herstad TK; McCallum L; Rosenqvist E; Oster P; Martin D
    Clin Vaccine Immunol; 2007 Jul; 14(7):830-8. PubMed ID: 17494638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Factor H Antibody Reactivity in Young Adults Vaccinated with a Meningococcal Serogroup B Vaccine Containing Factor H Binding Protein.
    Sharkey K; Beernink PT; Langley JM; Gantt S; Quach C; Dold C; Liu Q; Galvan M; Granoff DM
    mSphere; 2019 Jul; 4(4):. PubMed ID: 31270173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bactericidal killing of meningococcal W strains isolated in Argentina by the sera of adolescents and infants immunized with 4-component meningococcal serogroup B vaccine (4CMenB).
    Efron A; Biolchi A; Sorhouet Pereira C; Tomei S; Campos J; De Belder D; Moscoloni MA; Santos M; Vidal G; Nocita F; Vizzotti C; Pizza M
    Hum Vaccin Immunother; 2023 Dec; 19(3):2288389. PubMed ID: 38111094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents.
    Vesikari T; Østergaard L; Diez-Domingo J; Wysocki J; Flodmark CE; Beeslaar J; Eiden J; Jiang Q; Jansen KU; Jones TR; Harris SL; O'Neill RE; York LJ; Crowther G; Perez JL
    J Pediatric Infect Dis Soc; 2016 Jun; 5(2):152-60. PubMed ID: 26407272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.
    Vermont CL; van Dijken HH; Kuipers AJ; van Limpt CJ; Keijzers WC; van der Ende A; de Groot R; van Alphen L; van den Dobbelsteen GP
    Infect Immun; 2003 Apr; 71(4):1650-5. PubMed ID: 12654777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioinformatics Analysis of Global Diversity in Meningococcal Vaccine Antigens over the Past 10 Years: Vaccine Efficacy Prognosis.
    Savitskaya VY; Dolinnaya NG; Strekalovskikh VV; Peskovatskova ES; Snyga VG; Trefilov VS; Monakhova MV; Kubareva EA
    Med Sci (Basel); 2023 Dec; 11(4):. PubMed ID: 38132917
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase Variation of NadA in Invasive Neisseria meningitidis Isolates Impacts on Coverage Estimates for 4C-MenB, a MenB Vaccine.
    Green LR; Lucidarme J; Dave N; Chan H; Clark S; Borrow R; Bayliss CD
    J Clin Microbiol; 2018 Sep; 56(9):. PubMed ID: 29950334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains.
    Moe GR; Zuno-Mitchell P; Hammond SN; Granoff DM
    Infect Immun; 2002 Nov; 70(11):6021-31. PubMed ID: 12379678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine.
    Wedege E; Kuipers B; Bolstad K; van Dijken H; Frøholm LO; Vermont C; Caugant DA; van den Dobbelsteen G
    Infect Immun; 2003 Jul; 71(7):3775-81. PubMed ID: 12819059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and protective capacity of a CpG ODN adjuvanted alum adsorbed bivalent meningococcal outer membrane vesicle vaccine.
    Canavar Yildirim T; Ozsurekci Y; Yildirim M; Evcili I; Yazar V; Aykac K; Guler U; Salih B; Gursel M; Gursel I
    Int Immunol; 2024 Jul; 36(8):393-404. PubMed ID: 38536954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine.
    Katial RK; Brandt BL; Moran EE; Marks S; Agnello V; Zollinger WD
    Infect Immun; 2002 Feb; 70(2):702-7. PubMed ID: 11796602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.